Effect of point-of-care CD4 cell count tests on retention of patients and rates of antiretroviral therapy initiation in primary health clinics: an observational cohort study

BACKGROUND Loss to follow-up of HIV-positive patients before initiation of antiretroviral therapy can exceed 50% in low-income settings and is a challenge to the scale-up of treatment. We implemented point-of-care counting of CD4 cells in Mozambique and assessed the effect on loss to follow-up before immunological staging and treatment initiation. METHODS In this observational cohort study, data for enrolment into HIV management and initiation of antiretroviral therapy were extracted retrospectively from patients' records at four primary health clinics providing HIV treatment and point-of-care CD4 services. Loss to follow-up and the duration of each preparatory step before treatment initiation were measured and compared with baseline data from before the introduction of point-of-care CD4 testing. FINDINGS After the introduction of point-of-care CD4 the proportion of patients lost to follow-up before completion of CD4 staging dropped from 57% (278 of 492) to 21% (92 of 437) (adjusted odds ratio [OR] 0·2, 95% CI 0·15-0·27). Total loss to follow-up before initiation of antiretroviral treatment fell from 64% (314 of 492) to 33% (142 of 437) (OR 0·27, 95% CI 0·21-0·36) and the proportion of enrolled patients initiating antiretroviral therapy increased from 12% (57 of 492) to 22% (94 of 437) (OR 2·05, 95% CI 1·42-2·96). The median time from enrolment to antiretroviral therapy initiation reduced from 48 days to 20 days (p<0·0001), primarily because of a reduction in the median time taken to complete CD4 staging, which decreased from 32 days to 3 days (p<0·0001). Loss to follow-up between staging and antiretroviral therapy initiation did not change significantly (OR 0·84, 95% CI 0·49-1·45). INTERPRETATION Point-of-care CD4 testing enabled clinics to stage patients rapidly on-site after enrolment, which reduced opportunities for pretreatment loss to follow-up. As a result, more patients were identified as eligible for and initiated antiretroviral treatment. Point-of-care testing might therefore be an effective intervention to reduce pretreatment loss to follow-up. FUNDING Absolute Return for Kids and UNITAID.

[1]  S. Lawn,et al.  Linkage to HIV Care and Antiretroviral Therapy in Cape Town, South Africa , 2010, PloS one.

[2]  Stephen R Cole,et al.  Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies , 2009, The Lancet.

[3]  M. Maskew,et al.  Lost to follow up: contributing factors and challenges in South African patients on antiretroviral therapy. , 2007, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[4]  D. Mcintyre,et al.  Assessing efficiency and costs of scaling up HIV treatment , 2008, AIDS.

[5]  J. V. van Oosterhout,et al.  Evaluation of antiretroviral therapy results in a resource‐poor setting in Blantyre, Malawi , 2005, Tropical medicine & international health : TM & IH.

[6]  Matthias Egger,et al.  Electronic medical record systems, data quality and loss to follow-up: survey of antiretroviral therapy programmes in resource-limited settings. , 2008, Bulletin of the World Health Organization.

[7]  Elena Losina,et al.  Who starts antiretroviral therapy in Durban, South Africa?… not everyone who should , 2010, AIDS.

[8]  M. Dybul,et al.  Use of generic antiretroviral agents and cost savings in PEPFAR treatment programs. , 2010, JAMA.

[9]  Katherine Leach-Kemon,et al.  Financing of global health: tracking development assistance for health from 1990 to 2007 , 2009, The Lancet.

[10]  S. Jaffar,et al.  Mortality and loss-to-follow-up during the pre-treatment period in an antiretroviral therapy programme under normal health service conditions in Uganda , 2009, BMC public health.

[11]  S. Rosen,et al.  Retention in HIV Care between Testing and Treatment in Sub-Saharan Africa: A Systematic Review , 2011, PLoS medicine.

[12]  T. Peter,et al.  Accurate CD4 T-cell enumeration and antiretroviral drug toxicity monitoring in primary healthcare clinics using point-of-care testing , 2011, AIDS.

[13]  B. Lindtjørn,et al.  Patients Present Earlier and Survival Has Improved, but Pre-ART Attrition Is High in a Six-Year HIV Cohort Data from Ethiopia , 2010, PloS one.

[14]  B. Stilwell,et al.  Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2006 revision. , 2006 .

[15]  Kara Wools-Kaloustian,et al.  Viability and effectiveness of large-scale HIV treatment initiatives in sub-Saharan Africa: experience from western Kenya , 2006, AIDS.

[16]  R. Walensky,et al.  Scaling Up the 2010 World Health Organization HIV Treatment Guidelines in Resource-Limited Settings: A Model-Based Analysis , 2010, PLoS medicine.

[17]  D. Sridhar,et al.  Global health funding: how much, where it comes from and where it goes. , 2009, Health policy and planning.

[18]  J. Sterne,et al.  Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries , 2006, The Lancet.

[19]  A. Harries,et al.  Acceptance of Anti-Retroviral Therapy among Patients Infected with HIV and Tuberculosis in Rural Malawi Is Low and Associated with Cost of Transport , 2006, PloS one.

[20]  L. Myer,et al.  Rapid scale-up of a community-based HIV treatment service: programme performance over 3 consecutive years in Guguletu, South Africa. , 2006, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[21]  J. Pfeiffer,et al.  Loss to Follow-Up of Adults in Public HIV Care Systems in Central Mozambique: Identifying Obstacles to Treatment , 2009, Journal of acquired immune deficiency syndromes.

[22]  Kenneth A. Freedberg,et al.  The “ART” of Linkage: Pre-Treatment Loss to Care after HIV Diagnosis at Two PEPFAR Sites in Durban, South Africa , 2010, PloS one.

[23]  Sydney Rosen,et al.  Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007–2009: systematic review , 2010, Tropical medicine & international health : TM & IH.

[24]  D. Nash,et al.  Program-level and contextual-level determinants of low-median CD4+ cell count in cohorts of persons initiating ART in eight sub-Saharan African countries , 2011, AIDS.

[25]  L. Myer,et al.  Determinants of mortality and nondeath losses from an antiretroviral treatment service in South Africa: implications for program evaluation. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  M. Egger,et al.  Mortality of Patients Lost to Follow-Up in Antiretroviral Treatment Programmes in Resource-Limited Settings: Systematic Review and Meta-Analysis , 2009, PloS one.

[27]  M. Tanner,et al.  Improved antiretroviral treatment outcome in a rural African setting is associated with cART initiation at higher CD4 cell counts and better general health condition , 2011, BMC infectious diseases.

[28]  A. Hardon,et al.  Hunger, waiting time and transport costs: Time to confront challenges to ART adherence in Africa , 2007, AIDS care.

[29]  R. Walensky,et al.  Loss to Care and Death Before Antiretroviral Therapy in Durban, South Africa , 2009, Journal of acquired immune deficiency syndromes.

[30]  Jeffrey N. Martin,et al.  Diminishing Availability of Publicly Funded Slots for Antiretroviral Initiation among HIV-Infected ART-Eligible Patients in Uganda , 2010, PloS one.